Free Trial

Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

Sarepta Therapeutics logo
$17.10 -0.01 (-0.06%)
Closing price 06/30/2025 04:00 PM Eastern
Extended Trading
$17.15 +0.05 (+0.29%)
As of 07:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sarepta Therapeutics Stock (NASDAQ:SRPT)

Key Stats

Today's Range
$16.96
$17.52
50-Day Range
$17.10
$63.66
52-Week Range
$16.96
$162.95
Volume
4.59 million shs
Average Volume
2.14 million shs
Market Capitalization
$1.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.88
Consensus Rating
Hold

Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

SRPT MarketRank™: 

Sarepta Therapeutics scored higher than 94% of companies evaluated by MarketBeat, and ranked 66th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sarepta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 12 buy ratings, 12 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Sarepta Therapeutics has been the subject of 24 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Sarepta Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Sarepta Therapeutics are expected to grow by 309.74% in the coming year, from $2.67 to $10.94 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sarepta Therapeutics is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sarepta Therapeutics is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sarepta Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sarepta Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.90% of the float of Sarepta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Sarepta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Sarepta Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.90% of the float of Sarepta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Sarepta Therapeutics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 46 news articles for Sarepta Therapeutics this week, compared to 15 articles on an average week.
  • Search Interest

    Only 63 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.
  • MarketBeat Follows

    18 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.70% of the stock of Sarepta Therapeutics is held by insiders.

  • Percentage Held by Institutions

    86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sarepta Therapeutics' insider trading history.
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

Photo of Solid Biosciences logo and genes
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (SRPT)
After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.
Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
See More Headlines

SRPT Stock Analysis - Frequently Asked Questions

Sarepta Therapeutics' stock was trading at $121.59 on January 1st, 2025. Since then, SRPT shares have decreased by 85.9% and is now trading at $17.10.
View the best growth stocks for 2025 here
.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) posted its quarterly earnings results on Tuesday, May, 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by $5.62. The company's quarterly revenue was up 80.2% on a year-over-year basis.
Read the conference call transcript
.

Sarepta Therapeutics subsidiaries include these companies: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc..

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN).

Company Calendar

Last Earnings
5/06/2025
Today
7/01/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
1,372
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$60.88
High Stock Price Target
$160.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+256.0%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
25 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
6.40
P/E Growth
N/A
Net Income
$235.24 million
Pretax Margin
-7.35%

Debt

Sales & Book Value

Annual Sales
$1.90 billion
Cash Flow
$2.44 per share
Price / Cash Flow
7.02
Book Value
$15.99 per share
Price / Book
1.07

Miscellaneous

Free Float
90,710,000
Market Cap
$1.68 billion
Optionable
Optionable
Beta
0.61

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:SRPT) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners